Journal of Breast Cancer最新文献

{"title":"Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.","authors":"Ji-Jung Jung,&nbsp;Eun-Kyu Kim,&nbsp;Eunyoung Kang,&nbsp;Jee Hyun Kim,&nbsp;Se Hyun Kim,&nbsp;Koung Jin Suh,&nbsp;Sun Mi Kim,&nbsp;Mijung Jang,&nbsp;Bo La Yun,&nbsp;So Yeon Park,&nbsp;Changjin Lim,&nbsp;Wonshik Han,&nbsp;Hee-Chul Shin","doi":"10.4048/jbc.2023.26.e14","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e14","url":null,"abstract":"<p><strong>Purpose: </strong>Several predictive models have been developed to predict the pathological complete response (pCR) after neoadjuvant chemotherapy (NAC); however, few are broadly applicable owing to radiologic complexity and institution-specific clinical variables, and none have been externally validated. This study aimed to develop and externally validate a machine learning model that predicts pCR after NAC in patients with breast cancer using routinely collected clinical and demographic variables.</p><p><strong>Methods: </strong>The electronic medical records of patients with advanced breast cancer who underwent NAC before surgical resection between January 2017 and December 2020 were reviewed. Patient data from Seoul National University Bundang Hospital were divided into training and internal validation cohorts. Five machine learning techniques, including gradient boosting machine (GBM), support vector machine, random forest, decision tree, and neural network, were used to build predictive models, and the area under the receiver operating characteristic curve (AUC) was compared to select the best model. Finally, the model was validated using an independent cohort from Seoul National University Hospital.</p><p><strong>Results: </strong>A total of 1,003 patients were included in the study: 287, 71, and 645 in the training, internal validation, and external validation cohorts, respectively. Overall, 36.3% of the patients achieved pCR. Among the five machine learning models, the GBM showed the highest AUC for pCR prediction (AUC, 0.903; 95% confidence interval [CI], 0.833-0.972). External validation confirmed an AUC of 0.833 (95% CI, 0.800-0.865).</p><p><strong>Conclusion: </strong>Commonly available clinical and demographic variables were used to develop a machine learning model for predicting pCR following NAC. External validation of the model demonstrated good discrimination power, indicating that routinely collected variables were sufficient to build a good prediction model.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"353-362"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/15/jbc-26-353.PMC10475713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10511497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Norepinephrine/β₂-Adrenergic Receptor Pathway Promotes the Cell Proliferation and Nerve Growth Factor Production in Triple-Negative Breast Cancer.","authors":"Meihua Jin,&nbsp;Yan Wang,&nbsp;Tingting Zhou,&nbsp;Wenzhe Li,&nbsp;Qingping Wen","doi":"10.4048/jbc.2023.26.e25","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e25","url":null,"abstract":"<p><strong>Purpose: </strong>Invasive ductal carcinoma (IDC) accounts for 90% of triple-negative breast cancer (TNBC). IDC is mainly derived from the breast ductal epithelium which is innervated by the 4th to 6th thoracic sympathetic nerves. However, little is known about the contribution of the interactions between sympathetic nerves and breast cancer cells to the malignant progression of TNBC.</p><p><strong>Methods: </strong>The expression levels of the β₂-adrenergic receptor (β₂-AR, encoded by ADRB2 gene), nerve growth factor (NGF), and tropomyosin receptor kinase A (TrkA) were determined using immunohistochemistry (IHC). NGF expression levels in the serum were compared by enzyme-linked immunosorbent assay (ELISA). Cell proliferation was assessed using the Cell Counting Kit-8 assay. The β₂-AR, NGF, p-ERK, and p-CERB expression levels were determined using western blotting. TNBC cells and neuronal cells of the dorsal root ganglion (DRG) in 2-day-old Sprague Dawley rats were co-cultured. Using norepinephrine (NE), NGF, and β₂-AR, NGF/TrkA blocker pretreatments, the axon growth of each group of DRG neuron cells was detected by immunofluorescence analysis.</p><p><strong>Results: </strong>The sympathetic adrenergic neurotransmitter NE activated the ERK signaling pathway in TNBC cells. NE/β₂-AR signaling promotes NGF secretion. NGF further facilitates the malignant progression of TNBC by increasing sympathetic neurogenesis. In the co-culture assay, the sympathetic adrenergic NE/β₂-AR signal pathway also enhanced NGF secretion. NGF binds TrkA in DRG neurons and promotes axonal growth.</p><p><strong>Conclusion: </strong>These results suggest that NE/β₂-AR pathway promotes cell proliferation and NGF production in triple-negative breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"268-285"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/50/jbc-26-268.PMC10315331.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9750402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and Longitudinal Changes in the Practice of Breast Cancer Radiotherapy in Korea: Korean Radiation Oncology Group 22-01.","authors":"Hae Jin Park,&nbsp;Kyubo Kim,&nbsp;Yong Bae Kim,&nbsp;Jee Suk Chang,&nbsp;Kyung Hwan Shin","doi":"10.4048/jbc.2023.26.e15","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e15","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to analyze contemporary practice patterns in breast cancer radiotherapy (RT) and assess longitudinal changes over five years in Korea.</p><p><strong>Methods: </strong>In 2022, a nationwide survey was conducted among board-certified radiation oncologists. The survey consisted of 44 questions related to six domains: hypofractionated (HypoFx) whole breast RT, accelerated partial breast RT (APBI), regional nodal irradiation (RNI), RT for ductal carcinoma <i>in situ</i> (DCIS), postmastectomy RT (PMRT), and tumor bed boost.</p><p><strong>Results: </strong>Seventy radiation oncologists from 61 (out of 101; 60%) institutions participated in the survey. HypoFx RT was used by 62 respondents (89%), a significant increase from 36% in 2017. HypoFx RT is commonly administered at 40-42.5 Gy in 15-16 fractions. APBI was used by 12 respondents (17%), an increase from 5% in 2017. The use of RNI did not change significantly: ≥ pN2 (6%), ≥ pN1 (33%), and ≥ pN1 with pathological risk factors (61%). However, indications for internal mammary lymph node (IMN) irradiation have expanded. In particular, the rates of routine treatment of IMN (11% from 6% in 2017) and treatment in cases of ≥ pN2 (27% from 14% in 2017) have doubled; however, the rate of treatment for only IMN involvement, identified on imaging, has decreased from 47% in 2017 to 31%. For DCIS, the use of HypoFx RT increased from 25% in 2017 to 75%, and the rate of RT omissions after breast-conserving surgery (BCS) decreased from 48% in 2017 to 38%. The use of HypoFx RT for PMRT increased from 8% in 2017 to 36%.</p><p><strong>Conclusion: </strong>The adoption of HypoFx RT after BCS for invasive breast cancer and DCIS has increased significantly, whereas the use of HypoFx PMRT has increased moderately since 2017. However, further studies are required to determine the optimal use of RNI.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"254-267"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/93/jbc-26-254.PMC10315330.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9805588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anatomy Versus Physiology: Is Breast Lymphatic Drainage to the Internal Thoracic (Internal Mammary) Lymphatic System Clinically Relevant?","authors":"Priscilla Machado, Ji-Bin Liu, Laurence Needleman, Christine Lee, Flemming Forsberg","doi":"10.4048/jbc.2023.26.e16","DOIUrl":"10.4048/jbc.2023.26.e16","url":null,"abstract":"<p><p>Approximately 15%-25% of breast lymphatic drainage passes through the internal thoracic (internal mammary) lymphatic system, draining the inner quadrants of the breast. This study aimed to use lymphosonography to identify sentinel lymph nodes (SLNs) in the axillary and internal thoracic lymphatic systems in patients with breast cancer. Seventy-nine patients received subcutaneous ultrasound contrast agent injections around the tumor. Lymphosonography was used to identify SLNs. In 14 of the 79 patients (17.7%), the tumor was located in the inner quadrant of the breast. Lymphosonography identified 217 SLNs in 79 patients, averaging 2.7 SLNs per patient. The 217 identified SLNs in the 79 patients were located in the axillary lymphatic system; none were located in the internal thoracic (internal mammary) lymphatic system, although it was expected in two to four patients (i.e., 4-11 SLNs). These results implied that SLNs associated with breast cancer are predominantly located in the axillary lymphatic system.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"286-291"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/d6/jbc-26-286.PMC10315328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10341794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility Preservation in Young Women With Breast Cancer: A Review.","authors":"Yeon Hee Hong,&nbsp;Changhee Park,&nbsp;Haerin Paik,&nbsp;Kyung-Hun Lee,&nbsp;Jung Ryeol Lee,&nbsp;Wonshik Han,&nbsp;Seho Park,&nbsp;Seockhoon Chung,&nbsp;Hee Jeong Kim","doi":"10.4048/jbc.2023.26.e28","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e28","url":null,"abstract":"<p><p>Fertility preservation is a major concern in young patients diagnosed with breast cancer and planning to receive multimodality treatment, including gonadotoxic chemotherapy with or without age-related decline through long-term endocrine therapy. Most breast cancer patients undergo multimodality treatments; many short-term and long-term side effects arise during these therapies. One of the most detrimental side effects is reduced fertility due to gonadotoxic treatments with resultant psychosocial stress. Cryopreservation of oocytes, embryos, and ovarian tissue are currently available fertility preservation methods for these patients. As an adjunct to these methods, <i>in vitro</i> maturation or gonadotropin-releasing hormone agonist could also be considered. It is also essential to communicate well with patients in the decision-making process on fertility preservation. It is essential to refer patients diagnosed with breast cancer on time to fertility specialists for individualized treatment, which may lead to desirable outcomes. To do so, a multimodal team-based approach and in-depth discussion on the treatment of breast cancer and fertility preservation is crucial. This review aims to summarize infertility risk related to currently available breast cancer treatment, options for fertility preservation and its details, barriers to oncofertility counseling, and psychosocial issues.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"221-242"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/be/jbc-26-221.PMC10315332.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9741778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Breast Small Cell Carcinoma With Merkel Cell Features: A Case Report and Literature Review.","authors":"Ya Jiang,&nbsp;Ziran Gao,&nbsp;Yuanyuan Wang,&nbsp;Wenmang Xu","doi":"10.4048/jbc.2023.26.e24","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e24","url":null,"abstract":"<p><p>Neuroendocrine carcinoma of the breast is a rare malignant tumor which, with the features of Merkel cells is even rarer. Herein, we report a case of small cell carcinoma with Merkel cell features in a 52-year-old female. Microscopically, the tumor was characterized by diffuse and consistent small round cells that were de-adherent. The tumor cells had round or oval nuclei with delicate chromatin and small nucleoli, the cytoplasm was sparse and eosinophilic. Additionally, the tumor was accompanied by high-grade ductal carcinoma in situ. Immunohistochemical staining showed that infiltrating tumor cells were positive for neuroendocrine markers, and punctately positive for CK20. The patient underwent modified radical mastectomy, axillary lymph node dissection, and postoperative adjuvant chemotherapy. No recurrence or metastasis was observed during follow-up period. Primary breast small cell carcinoma with Merkel cell features is rare and easily misdiagnosed as Merkel cell carcinoma. Early diagnosis and treatment may improve patient prognosis.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"302-307"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/69/jbc-26-302.PMC10315333.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9805590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Decreased Quality of Life in Breast Cancer Survivors Five Years After Diagnosis.","authors":"Saskia-Laureen Herbert,&nbsp;Felix Flock,&nbsp;Ricardo Felberbaum,&nbsp;Wolfgang Janni,&nbsp;Sanja Löb,&nbsp;Matthias Kiesel,&nbsp;Tanja Schlaiß,&nbsp;Joachim Diessner,&nbsp;Carolin Curtaz,&nbsp;Ralf Joukhadar,&nbsp;Davut Dayan,&nbsp;Lukas Schwentner,&nbsp;Susanne Singer,&nbsp;Achim Wöckel","doi":"10.4048/jbc.2023.26.e23","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e23","url":null,"abstract":"<p><strong>Purpose: </strong>Due to improved therapy, early diagnosis, and growing incidence rates, the number of long-term breast cancer survivors is increasing. Survivors can still be affected by aftercare, resulting in reduced quality of life (QoL). Thus, in this study, we investigated possible predictors of decreased physical and social functioning in breast cancer survivors.</p><p><strong>Methods: </strong>In a German multicenter prospective study, we enrolled 759 female patients with breast cancer before surgery (t1), and contacted them again 5 years after surgery (t4). Data on QoL were assessed at t4 using the European Organization for Research and Treatment of Cancer QoL Core Questionnaire (EORTC QLQ-C30) and its breast cancer module EORTC QLQ-BR23. Predictors of decreased physical and social functioning were analyzed using logistic regression with odds ratios as effect estimates and 95% confidence intervals. Thresholds for the clinical importance of detrimental effects on QoL were defined according to Giesinger.</p><p><strong>Results: </strong>Questionnaires from 759 patients were retrieved at t1. Of these, 456 participated in the study at t4. Poor QoL 5 years after diagnosis was reported by 20%-50% of the participants. Age, mastectomy, chemotherapy, education, employment, cohabitation, psychiatric comorbidities at t1, anxiety, depression, and intensity of physical activity emerged as predictors of decreased physical and social functioning 5 years after diagnosis.</p><p><strong>Conclusion: </strong>Relief of symptoms and improvement in the QoL should be priorities in aftercare. Detecting patients with a decreased QoL is a rising challenge. Healthcare providers should take special care of patients aged 50-59 years, patients with psychiatric comorbidities and depression, and patients who have undergone mastectomy.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"243-253"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/d6/jbc-26-243.PMC10315334.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9805591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffusion-Weighted Magnetic Resonance Imaging for Preoperative Evaluation of Patients With Breast Cancer: Protocol of a Prospective, Multicenter, Observational Cohort Study.","authors":"Vivian Youngjean Park,&nbsp;Hee Jung Shin,&nbsp;Bong Joo Kang,&nbsp;Min Jung Kim,&nbsp;Woo Kyung Moon,&nbsp;Sung Eun Song,&nbsp;Su Min Ha","doi":"10.4048/jbc.2023.26.e18","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e18","url":null,"abstract":"<p><strong>Purpose: </strong>Detection of multifocal, multicentric, and contralateral breast cancers in patients affects surgical management. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can identify additional foci that were initially undetected by conventional imaging. However, its use is limited owing to low specificity and high false-positive rate. Multiparametric MRI (DCE-MRI + diffusion-weighted [DW] MRI) can increase the specificity. We aimed to describe the protocols of our prospective, multicenter, observational cohort studies designed to compare the diagnostic performance of DCE-MRI and multiparametric MRI for the diagnosis of multifocal, multicentric cancer and contralateral breast cancer in patients with newly diagnosed breast cancer.</p><p><strong>Methods: </strong>Two studies comparing the performance of DCE-MRI and multiparametric MRI for the diagnosis of multifocal, multicentric cancer (NCT04656639) and contralateral breast cancer (NCT05307757) will be conducted. For trial NCT04656639, 580 females with invasive breast cancer candidates for breast conservation surgery whose DCE-MRI showed additional suspicious lesions (breast imaging reporting and data system [BI-RADS] category ≥ 4) on DCE-MRI in the ipsilateral breast will be enrolled. For trial NCT05307757, 1098 females with invasive breast cancer whose DCE-MRI showed contralateral lesions (BI-RADS category ≥ 3 or higher on DCE-MRI) will be enrolled. Participants will undergo 3.0-T DCE-MRI and DW-MRI. The diagnostic performance of DCE-MRI and multiparametric MRI will be compared. The receiver operating characteristic curve, sensitivity, specificity, positive predictive value, and characteristics of the detected cancers will be analyzed. The primary outcome is the difference in the receiver operating characteristic curve between DCE-MRI and multiparametric MRI interpretation. Enrollment completion is expected in 2024, and study results are expected to be presented in 2026.</p><p><strong>Discussion: </strong>This prospective, multicenter study will compare the performance of DCE-MRI versus multiparametric MRI for the preoperative evaluation of multifocal, multicentric, and contralateral breast cancer and is currently in the patient enrollment phase.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT04656639, NCT05307757. Registered on April 1 2022.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"292-301"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/f8/jbc-26-292.PMC10315329.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10341796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Statistics in Korea, 2019.","authors":"Jung Eun Choi,&nbsp;Zisun Kim,&nbsp;Chan Sub Park,&nbsp;Eun Hwa Park,&nbsp;Sae Byul Lee,&nbsp;Se Kyung Lee,&nbsp;Young Jin Choi,&nbsp;Jaihong Han,&nbsp;Kyu-Won Jung,&nbsp;Hee Jeong Kim,&nbsp;Hyun-Ah Kim","doi":"10.4048/jbc.2023.26.e27","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e27","url":null,"abstract":"<p><p>This article provides an annual update of Korean breast cancer statistics, including the incidence, tumor stage, type of surgical treatment, and mortality. The data was collected from the Korean Breast Cancer Society registry system and Korean Central Cancer Registry. In 2019, 29,729 women were newly diagnosed with breast cancer. Breast cancer has continued to increase in incidence since 2002 and been the most common cancer in Korean women since 2019. Of the newly diagnosed cases in 2019, 24,820 (83.5%) were of invasive carcinomas, and 4,909 (16.5%) were of carcinoma <i>in situ</i>. The median age of women with breast cancer was 52.8 years, and breast cancer was most commonly diagnosed in the age group of 40-49 years. The number of patients who have undergone breast conserving surgery has continued to increase since 2016, with 68.6% of patients undergoing breast conserving surgery in 2019. The incidence of early-stage breast cancer continues to increase, with stage 0 or I breast cancer accounting for 61.6% of cases. The most common subtype of breast cancer is the hormone receptor-positive human epidermal growth factor receptor 2-negative subtype (63.1%). The 5-year relative survival rate of patients with breast cancer from 2015 to 2019 was 93.6%, with an increase of 14.3% compared to that from 1993 to 1995. This report improves our understanding of breast cancer characteristics in South Korea.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"207-220"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e9/jbc-26-207.PMC10315335.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9747887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of Tumor Growth and Metastasis by Newcastle Disease Virus Strain P05 in a Breast Cancer Mouse Model.","authors":"Oscar Antonio Ortega-Rivera,&nbsp;Pamela Gallegos-Alcalá,&nbsp;Mariela Jiménez,&nbsp;J Luis Quintanar,&nbsp;Flor Torres-Juarez,&nbsp;Bruno Rivas-Santiago,&nbsp;Susana Del Toro-Arreola,&nbsp;Eva Salinas","doi":"10.4048/jbc.2023.26.e9","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e9","url":null,"abstract":"<p><strong>Purpose: </strong>Conventional therapies and surgery remain the standard treatment for breast cancer. However, combating the eventual development of metastasis is still a challenge. Newcastle disease virus (NDV) is one of the various species of viruses under clinical evaluation as a vector for oncolytic, gene-, and immune-stimulating therapies. The purpose of this study was to evaluate the antitumor activity of a recombinant NDV (rNDV-P05) in a breast cancer murine model.</p><p><strong>Methods: </strong>Tumors were induced by injecting the cellular suspension (4T1 cell line) subcutaneously. The virus strain P05 was applied three times at intervals of seven days, starting seven days after tumor induction, and was completed 21 days later. Determination of tumor weight, spleen index, and lung metastasis were done after sacrificing the mice. Serum levels of interferon (IFN)-α, IFN-γ, tumor necrosis factor (TNF)-α, and TNF-related apoptosis-inducing ligand (TRAIL) were quantified by enzyme-linked immunosorbent assay. CD8+ infiltrated cells were analyzed by immunofluorescence.</p><p><strong>Results: </strong>rNDV-P05 showed a route-of-administration-dependent effect, demonstrating that the systemic administration of the virus significantly reduces the tumor mass and volume, spleen index, and abundance of metastatic clonogenic colonies in lung tissue, and increases the inhibition rate of the tumor. The intratumoral administration of rNDV-P05 was ineffective for all the parameters evaluated. Antitumor and antimetastatic capability of rNDV-P05 is mediated, at least partially, through its immune-stimulatory effect on the upregulation of TNF-α, TRAIL, IFN-α, and IFN-γ, and its ability to recruit CD8+ T cells into tumor tissue.</p><p><strong>Conclusion: </strong>Systemic treatment with rNDV-P05 decreases the tumoral parameters in the breast cancer murine model.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 2","pages":"186-200"},"PeriodicalIF":2.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/c8/jbc-26-186.PMC10139849.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9715843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}